Biogen Inc.
BIIBHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeBiogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The $30.41B market capitalization puts BIIB squarely in large-cap range for its industry. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Market Cap
$30.41B
Beta
0.16
P/E (TTM)
22.15
P/E (Fwd)
12.45
EPS (TTM)
$9.30
EPS (Fwd)
$16.55
ROE
7.7%
ROA
5.9%
Cash
$4.28B
Total Debt
$6.56B
Free CF
$1.93B
52W Change
64.8%
Annual Financials
Cash vs Debt
Biogen Inc. carries $6.56B in total debt against $4.28B in cash reserves — debt is roughly 1.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $1.93B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 7.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $10.17B (2022) to $9.89B (2025).
BIIB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biogen Inc. and its sector.